Press Releases

Keyword Search

DateTitle 
10/09/14

DANVERS, Mass., Oct. 9, 2014 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD) announced today that on Thursday, October 30, 2014, the Company will release financial results for the second quarter of fiscal 2015. The Company will host a conference call to discuss the results on Thursday, October 30, 2014, at 8:00 a.m. ET. Michael R. Minogue, Chairman...

Print Page
09/18/14

DANVERS, Mass., Sept. 18, 2014 (GLOBE NEWSWIRE) -- Abiomed Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced the appointment of Ingrid Goldberg, as Director of Investor Relations.  "We are extremely pleased to have Ingrid on board during a pivotal time of growth and opportunity for the Company," ...

Print Page
09/16/14

WASHINGTON, Sept. 16, 2014 (GLOBE NEWSWIRE) -- Abiomed Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced clinical trial results from RECOVER RIGHT, an Investigational Device Exemption (IDE) study of the Impella RP™ (Right Percutaneous) System. The clinical trial results demonstrated a survival ...

Print Page
09/10/14

DANVERS, Mass., Sept. 10, 2014 (GLOBE NEWSWIRE) -- Abiomed Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, announced that data from RECOVER RIGHT, an Investigational Device Exemption (IDE) study of the Impella RP™ (Right Peripheral) System, will be released during the scientific sessions at the Cardiovascula...

Print Page
09/03/14

DANVERS, Mass., Sept. 3, 2014 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will present at the Morgan Stanley Global Healthcare Conference on September 10, 2014 at 10:20 a.m. EDT. The conferenc...

Print Page
07/31/14

DANVERS, Mass., July 31, 2014 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today reported first quarter fiscal 2015 revenue of $48.8 million, an increase of 14% compared to revenue of $42.7 million for the same period of fiscal 2014. First quarter fiscal 2015 GAAP net loss was $1.7 ...

Print Page
07/01/14

DANVERS, Mass., July 1, 2014 (GLOBE NEWSWIRE) -- Abiomed, Inc. (ABMD), a leading provider of breakthrough heart sup...

Print Page
06/04/14

DANVERS, Mass., June 4, 2014 (GLOBE NEWSWIRE) -- The MedTech and BioTech Veterans Program (MVP) announced today it will host the Boston area's first-ever Student Veteran Re-careering Seminar for alumni and student military veterans interested in pursuing careers in the life sciences. MVP is a newly-expanded nationwide initiative designed to pro...

Print Page
06/04/14

DANVERS, Mass., June 4, 2014 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will present at the William Blair Growth Stock Conference on June 11, 2014 at 10:40 a.m. CDT. The conference will be he...

Print Page
06/03/14

DANVERS, Mass., June 3, 2014 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today reported that physicians have implanted more than 20,000 Impella® pumps in U.S. patients requiring hemodynamic support. The 20,000th Impella procedure took place at Keck Medicine of University of So...

Print Page
05/27/14

DANVERS, Mass., May 27, 2014 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will present at the Jefferies 2014 Global Healthcare Conference on June 2, 2014 at 2:00 p.m. EDT. The conference will b...

Print Page
05/21/14

DANVERS, Mass., May 21, 2014 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced it has received approval for implementation of a Continuous Access Protocol (CAP) from the Food & Drug Administration (FDA) for RECOVER RIGHT, an Investigational Device Exemption (IDE) study of...

Print Page
05/19/14

DANVERS, Mass., May 19, 2014 (GLOBE NEWSWIRE) -- Abiomed Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, notes that there will be approximately eight potential Impella-related presentations in the scientific sessions at the annual EuroPCR 2014 cardiovascular course, scheduled from May 20 - 23, 2014 at the Palais D...

Print Page
05/01/14

Record Patient Utilization and 200% Growth in Impella CP PatientsAbiomed Completes Impella 2.5 Submission for Pre-Market Approval (PMA) DANVERS, Mass., May 1, 2014 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today reported fourth quarter fiscal 2014 revenue of $50.4 million, u...

Print Page
04/15/14

DANVERS, Mass., April 15, 2014 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of break-through heart support technologies, today announced its acquisition of an exclusive license from collaboration partner Opsens (TSX-V:OPS), a leading developer of fiber optic sensors. Through this exclusive licensing agreement, which covers th...

Print Page
04/10/14

DANVERS, Mass., April 10, 2014 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD) announced today that on Thursday, May 1, 2014, the Company will release financial results for the fourth quarter of fiscal 2014. The Company will host a conference call to discuss the results on Thursday, May 1, 2014, at 8:00 a.m. ET. Michael R. Minogue, Chairman, Presid...

Print Page
04/08/14

DANVERS, Mass., April 8, 2014 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of break-through heart support technologies, today announced it has received CE Marking approval in the European Union to market the Impella® RP device, a new percutaneous Impella heart pump that provides temporary ventricular support for patients...

Print Page
03/27/14

DANVERS, Mass., March 27, 2014 (GLOBE NEWSWIRE) -- Abiomed Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, will be attending and exhibiting at the American College of Cardiology (ACC) annual 2014 scientific sessions, scheduled from March 29 - 31, at the Walter E. Washington Convention Center in Washington, DC. ...

Print Page
03/21/14

DANVERS, Mass., March 21, 2014 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced that the Centers for Medicare & Medicaid Services (CMS) has released an updated version of ICD-10 MS-DRGs (version 31R) and maintained assignment to Diagnosis Related Groups (MS-DRGs) 216-221...

Print Page
03/20/14

DANVERS, Mass., March 20, 2014 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced the completion of the 30th patient enrolled in RECOVER RIGHT, an Investigational Device Exemption (IDE) study of Impella® RP (Right Peripheral). The trial was designed to enroll as many ...

Print Page
02/05/14

- Offers Advanced Educational Resources and Training for Veteran Recruits - New Web Portal Address: www.mvpvets.org CARLSBAD, Calif., Feb. 5, 2014 (GLOBE NEWSWIRE) -- The Medical Technology Veterans Program, renamed the MedTech and BioTech Veterans Program (MVP), has expanded nationwide and to industries across the life sciences. MVP is a c...

Print Page
02/05/14

DANVERS, Mass., Feb. 5, 2014 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer will present at the Leerink Global Healthcare Conference 2014, February 12 at 1:00 p.m. EST. The conference will be held...

Print Page
01/30/14

Abiomed Receives Approval in China for Impella 2.5, Impella 5.0 and MPC DANVERS, Mass., Jan. 30, 2014 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today reported third quarter fiscal 2014 revenue of $46.2 million, up 21% compared to revenue of $38.3 million in the same period of fis...

Print Page
01/09/14

DANVERS, Mass., Jan. 9, 2014 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD) announced today that on Thursday, January 30, 2014, the Company will release financial results for the third quarter of fiscal 2014. The Company will host a conference call to discuss the results on Thursday, January 30, 2014, at 8:00 a.m. ET. Michael R. Minogue, Chairman,...

Print Page
11/26/13

DANVERS, Mass., Nov. 26, 2013 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will present at the 25th Annual Piper Jaffray Healthcare Conference, December 4, 2013 at 8:00 a.m. EST. The conference...

Print Page
11/07/13

DANVERS, Mass., Nov. 7, 2013 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced that Robert L. Bowen, Vice President and Chief Financial Officer, and Susan V. Lisa, Senior Director, Investor Relations and Corporate Development, will present at the 2013 Credit Suisse Health...

Print Page
11/06/13

DANVERS, Mass., Nov. 6, 2013 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today reported second quarter fiscal 2014 revenue of $44.3 million, up 19% compared to revenue of $37.4 million in the same period of fiscal 2013, and a second quarter fiscal 2014 GAAP net income of $1.1 milli...

Print Page
11/05/13

DANVERS, Mass., Nov. 5, 2013 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced that Robert L. Bowen, Vice President and Chief Financial Officer, and Susan V. Lisa, Senior Director, Investor Relations and Corporate Development, will present at the Stephens Fall Investment ...

Print Page
10/23/13

DANVERS, Mass., Oct. 23, 2013 (GLOBE NEWSWIRE) -- Abiomed Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, notes that there will be over 25 potential Impella presentations in the scientific sessions at the Cardiovascular Research Foundation's (CRF) annual Transcatheter Cardiovascular Therapeutics (TCT) 2013 scienti...

Print Page
10/16/13

DANVERS, Mass., Oct. 16, 2013 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD) announced today that on Wednesday, November 6, 2013, the Company will release financial results for the second quarter of fiscal 2014. The Company will host a conference call to discuss the results on Wednesday, November 6, 2013, at 8:00 a.m. ET. Michael R. Minogue, Chair...

Print Page
10/01/13

DANVERS, Mass., Oct. 1, 2013 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today reported its donation of an unrestricted grant in the amount of $375,000 to Boston Children's Hospital Heart Center, a newly dedicated cardiovascular care center founded within Boston Children's Hospital...

Print Page
09/11/13

DANVERS, Mass., Sept. 11, 2013 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced that Susan V. Lisa, Senior Director, Investor Relations and Corporate Development, will present at the 4th Annual Credit Suisse Small & Mid Cap Conference on Wednesday, September 18, 2013 at ...

Print Page
09/03/13

DANVERS, Mass., Sept. 3, 2013 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer will present at the Morgan Stanley Global Healthcare Conference on Tuesday, September 10, 2013 at 11:45 a.m. ET. The co...

Print Page
08/26/13

DANVERS, Mass., Aug. 26, 2013 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today reported that it received approval from the U.S. Department of Veterans Affairs to be included on its authorized Veteran's Administration (VA) Federal Supply Schedule in which Abiomed can provide the Im...

Print Page
08/02/13

DANVERS, Mass., Aug. 2, 2013 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today reported that physicians have implanted more than 15,000 Impella® pumps in U.S. patients requiring hemodynamic support. The 15,000th Impella procedure took place at Mercy General Hospital in Sacrame...

Print Page
08/01/13

DANVERS, Mass., Aug. 1, 2013 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today reported first quarter fiscal 2014 revenue of $42.7 million, up 10% compared to revenue of $38.8 million in the same period of fiscal 2013, and a first quarter fiscal 2014 GAAP net loss of $1.7 million o...

Print Page
07/11/13

DANVERS, Mass., July 11, 2013 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD) announced today that on Thursday, August 1, 2013, the Company will release financial results for the first quarter of fiscal 2014. The Company will host a conference call to discuss the results on Thursday, August 1, 2013, at 8:00 a.m. ET. Michael R. Minogue, Chairman, Pr...

Print Page
06/06/13

DANVERS, Mass., June 6, 2013 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced that Robert L. Bowen, Vice President & CFO, will present at the Goldman Sachs 34th Annual Global Healthcare Conference on Thursday, June 13, 2013 at 10:00 a.m. PDT. The conference will be held ...

Print Page
06/05/13

DANVERS, Mass., June 5, 2013 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will present at the William Blair 33rd Annual Growth Stock Conference on Wednesday, June 12, 2013 at 8:40 a.m. CDT. The...

Print Page
05/28/13

DANVERS, Mass., May 28, 2013 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced that the Netherlands has approved new reimbursement coding and payment for the Impella product. The new coding allows for hospitals to receive funding f...

Print Page
05/22/13

DANVERS, Mass., May 22, 2013 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced that Susan V. Lisa, Senior Director, Investor Relations and Corporate Development, will present at the Deutsche Bank 38th Annual Health Care Conference on Wednesday, May 29, 2013 at 2:50 p.m. E...

Print Page
05/17/13

DANVERS, Mass., May 17, 2013 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced that Susan V. Lisa, Senior Director, Investor Relations and Corporate Development, will present at the UBS Global Health Care Conference on Wednesday, May 22, 2013 at 10:00 a.m. ET. The confere...

Print Page
05/08/13

DANVERS, Mass., May 8, 2013 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced that Susan V. Lisa, Senior Director, Investor Relations and Corporate Development, will present at the Bank of America Merrill Lynch 2013 Health Care Conference on Wednesday, May 15, 2013 at 9:2...

Print Page
05/03/13

DANVERS, Mass., May 3, 2013 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced that Susan V. Lisa, Senior Director, Investor Relations and Corporate Development, will present at the Bank of America Merrill Lynch 2013 Smid Cap Conference on Tuesday, May 7, 2013 at 3:50 p.m....

Print Page
05/02/13

DANVERS, Mass., May 2, 2013 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today reported fourth quarter fiscal 2013 revenue of $43.7 million, up 17% compared to revenue of $37.3 million in the same period of fiscal 2012, and fourth quarter fiscal 2013 GAAP net income of $3.7 million ...

Print Page
05/01/13

DANVERS, Mass., May 1, 2013 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced the publication of the PROTECT II Cost Effectiveness Study in the American Health & Drug Benefits (AHDB) journal, titled "A Value-Based Analysis of Hemodynamic Support Strategies for High-Risk H...

Print Page
04/17/13

DANVERS, Mass., April 17, 2013 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today reported preliminary fourth quarter fiscal 2013 revenue of $43.7 million, up 17% compared to revenue of $37.3 million in the same period of fiscal 2012, and up 14% compared to revenue of $38.3 million ...

Print Page
04/01/13

DANVERS, Mass., April 1, 2013 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced the enrollment of the first patient in RECOVER RIGHT, an Investigational Device Exemption (IDE) study of Impella® RP (Right Peripheral). The Impella RP is a percutaneous heart pump th...

Print Page
03/07/13

DANVERS, Mass., March 7, 2013 (GLOBE NEWSWIRE) -- Abiomed Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, notes that there will be over 15 Impella presentations in the scientific sessions at the annual American College of Cardiology (ACC) 2013 scientific meeting, scheduled from March 9 - 11, at the Moscone Convent...

Print Page
03/07/13

DANVERS, Mass., March 7, 2013 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced that Susan V. Lisa, Senior Director, Investor Relations and Corporate Development, will present at the Barclays Global Healthcare Conference on Thursday, March 14, 2013 at 9:00 a.m. ET. The co...

Print Page
03/04/13

Four Commercial Insurers Institute Broad Impella CoverageImpella Economic Study Published in The Journal of Managed Care Medicine (JMCM) DANVERS, Mass., March 4, 2013 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today provided a reimbursement update. Abiomed announced several re...

Print Page
02/27/13

DANVERS, Mass., Feb. 27, 2013 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced that Susan V. Lisa, Senior Director, Investor Relations and Corporate Development, will present at the Cowen and Company 33rd Annual Health Care Conference on Wednesday, March 6, 2013 at 10:40...

Print Page
02/20/13

DANVERS, Mass., Feb. 20, 2013 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced that on February 19, 2013, Abiomed received a close-out letter from the Food and Drug Administration, Office of Compliance with respect to its previous FDA warning letter dated June 10, 2011. ...

Print Page
02/07/13

DANVERS, Mass., Feb. 7, 2013 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will present at the Leerink Swann Global Healthcare Conference 2013 on Wednesday, February 13, 2013 at 8:00 a.m. ET. Th...

Print Page
02/06/13

DANVERS, Mass., Feb. 6, 2013 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today reported third quarter fiscal 2013 revenue of $38.3 million, up 19% compared to revenue of $32.2 million in the same period of fiscal 2012, on record quarterly patient usage, up 26% compared to the same ...

Print Page
01/17/13

DANVERS, Mass., Jan. 17, 2013 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD) announced today that on Wednesday, February 6, 2013, the Company will release financial results for the third quarter of fiscal 2013. The Company will host a conference call to discuss the results on Wednesday, February 6, 2013, at 8:00 a.m. ET. Michael R. Minogue, Chairm...

Print Page
12/06/12

DANVERS, Mass., Dec. 6, 2012 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced that the U.S. Food and Drug Administration's (FDA) Circulatory System Devices Panel voted to retain Class III status for the temporary ventricular support devices within the non-roller type car...

Print Page
11/21/12

DANVERS, Mass., Nov. 21, 2012 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will present at the 24th Annual Piper Jaffray Healthcare Conference on Wednesday, November 28, 2012 at 8:00 a.m. EST. ...

Print Page
11/16/12

DANVERS, Mass., Nov. 16, 2012 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced that a purported class action complaint was filed on November 16, 2012 in the United States District Court for the District of Massachusetts by Karse Simon and Arlene Simon, on behalf of thems...

Print Page
11/13/12

DANVERS, Mass., Nov. 13, 2012 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced that its Board of Directors has authorized a stock repurchase program of up to $15 million of its common stock. Abiomed will finance the stock repurchase program with available cash. The C...

Print Page
11/12/12

WASHINGTON, D.C. - The Advanced Medical Technology Association (AdvaMed) today launched MedicalTechnologyVeterans.org, a web portal that links job-seeking veterans to mentors and recruiters in the medical technology industry. The website is an extension of the Medical Technology Vete...

Print Page
11/12/12

DANVERS, Mass., Nov. 12, 2012 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, announced today that it received Investigational Device Exemption (IDE) approval from the Food & Drug Administration (FDA) for the use of the new Impella® RP (Right-side Percutaneous) in a pivotal clinic...

Print Page
11/09/12

DANVERS, Mass., Nov. 9, 2012 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced that Susan V. Lisa, Senior Director, Investor Relations and Corporate Development, will present at the 2012 Credit Suisse Annual Health Care Conference on Wednesday, November 14, 2012 at 4:30 p...

Print Page
11/07/12

DANVERS, Mass., Nov. 7, 2012 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will present at the Lazard Capital Markets 9th Annual Healthcare Conference on Tuesday, November 13, 2012 at 10:30 a.m....

Print Page
11/02/12

DANVERS, Mass., Nov. 2, 2012 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, announced today that the Department of Health and Human Services, through the Centers for Medicare and Medicaid Services (CMS), has approved and released the valuation of the three new Category I Current Proce...

Print Page
11/01/12

Record GAAP Profitability of $5.5 Million or $0.13 Per Diluted Share DANVERS, Mass., Nov. 1, 2012 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today reported second quarter fiscal 2013 revenue of $37.4 million, up 27% compared to revenue of $29.5 million in the same period of fi...

Print Page
10/30/12

DANVERS, Mass., Oct. 30, 2012 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a ...

Print Page
10/30/12

DANVERS, Mass., Oct. 30, 2012 (GLOBE NEWSWIRE) -- In response to the effects of Hurricane Sandy on the East Coast and the related close of the trading markets, ...

Print Page
10/23/12

DANVERS, Mass., Oct. 23, 2012 (GLOBE NEWSWIRE) -- Abiomed,Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologie...

Print Page
10/15/12

DANVERS, Mass., Oct. 15, 2012 (GLOBE NEWSWIRE) -- Abiomed Inc. (Nasdaq:ABMD), a lead...

Print Page
10/11/12

DANVERS, Mass., Oct. 11, 2012 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD) ann...

Print Page
10/01/12

Boston—AdvaMed 2012: The MedTech Conference—October 1, 2012—The Advanced Medical Technology Association (AdvaMed) today announced the launch of the Medical Technology Veterans Program (MVP) Boot Camp for Returning Heroes, a year-long career tra...

Print Page
09/12/12

DANVERS, Mass., Sept. 12, 2012 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a...

Print Page
09/11/12

DANVERS, Mass., Sept. 11, 2012 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a...

Print Page
09/10/12

DANVERS, Mass., Sept. 10, 2012 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a...

Print Page
09/06/12

DANVERS, Mass., Sept. 6, 2012 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:...

Print Page
09/04/12

DANVERS, Mass., Sept. 4, 2012 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a...

Print Page
09/04/12

DANVERS, Mass., Sept. 4, 2012 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a...

Print Page
08/02/12

DANVERS, Mass., Aug. 2, 2012 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a ...

Print Page
07/12/12

DANVERS, Mass., July 12, 2012 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD) announced today that on Thursday, August 2, 2012, the Company will release financial results for the first quarter of fiscal...

Print Page
06/14/12

DANVERS, Mass., June 14, 2012 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of break-through heart support technologies, today announced it has received Health Canada approval to marke...

Print Page
06/13/12

DANVERS, Mass., June 13, 2012 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, Preside...

Print Page
05/31/12

DANVERS, Mass., May 31, 2012 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced that Susie Lisa, Senior Director, Investor ...

Print Page
05/29/12

DANVERS, Mass., May 29, 2012 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, Presiden...

Print Page
05/16/12

DANVERS, Mass., May 16, 2012 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD - ...

Print Page
05/10/12

DANVERS, Mass., May 10, 2012 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced that Susie Lisa, Senior Director, Investor ...

Print Page
05/08/12

DANVERS, Mass., May 8, 2012 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD) announced today that on Wednesday, May 16, 2012, the Company will release financial results for the fourth quarter and full ye...

Print Page
05/08/12

DANVERS, Mass., May 8, 2012 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of break-through heart support technologies, today announced its participation in three upcoming physician society meetin...

Print Page
05/01/12

DANVERS, Mass., May 01, 2012 (BUSINESS WIRE) --Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart ...

Print Page
04/12/12

DANVERS, Mass., Apr 12, 2012 (BUSINESS WIRE) --Abiomed, Inc. (NASDAQ: ABMD), a leading provider of break-through heart s...

Print Page
04/03/12

DANVERS, Mass.--(BUSINESS WIRE)--Apr. 3, 2012-- ...

Print Page